Acta Neuropathologica

, Volume 112, Issue 2, pp 205–215

Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases

  • Annett Hölsken
  • Ilker Y. Eyüpoglu
  • Mike Lueders
  • Christian Tränkle
  • Detlef Dieckmann
  • Rolf Buslei
  • Eric Hahnen
  • Ingmar Blümcke
  • Florian A. Siebzehnrübl
Original Paper

DOI: 10.1007/s00401-006-0082-8

Cite this article as:
Hölsken, A., Eyüpoglu, I.Y., Lueders, M. et al. Acta Neuropathol (2006) 112: 205. doi:10.1007/s00401-006-0082-8

Abstract

Disease progression in patients suffering from malignant melanomas is often determined by metastatic spreading into brain parenchyma. Systemic chemotherapy regimens are, therefore, mandatory for successful treatment. Most recently, inhibitors of histone deacetylases (HDACi) have been shown to significantly inhibit melanoma progression. Here, mouse as well as human melanoma cells were transplanted into rodent hippocampal slice cultures in order to translate and microscopically confirm promising in vitro chemotherapeutic propensities of HDACi within the organotypic brain environment. In our ex vivo model, tumor progression was significantly inhibited by administration of low micromolar concentrations of second generation HDACi MS-275 over a period of 8 days. In contrast, HDACi treatment with suberoylanilide hydroxamic acid was less efficient ex vivo, although both compounds were successful in the treatment of tumor cell monolayer cultures. Protein levels of the cell cycle inhibitor p21WAF1 were significantly increased after HDACi treatment, which points to enhanced G1 arrest of tumor cells as confirmed by cytofluorometric analysis. Considering the ability of MS-275 to cross the blood–brain barrier, our experimental model identifies the benzamide MS-275 as a promising therapeutic compound for targeting epigenetic chromatin modulation as systemic treatment of metastatic melanomas.

Keywords

MS-275 Valproic acid SAHA M344 Hippocampus p21 Melanoma metastases 

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Annett Hölsken
    • 1
  • Ilker Y. Eyüpoglu
    • 2
  • Mike Lueders
    • 3
  • Christian Tränkle
    • 4
  • Detlef Dieckmann
    • 5
  • Rolf Buslei
    • 1
  • Eric Hahnen
    • 1
    • 6
  • Ingmar Blümcke
    • 1
  • Florian A. Siebzehnrübl
    • 1
  1. 1.Department of NeuropathologyUniversity of Erlangen-NurembergErlangenGermany
  2. 2.Department of NeurosurgeryUniversity of Erlangen-NurembergErlangenGermany
  3. 3.Department of Medicine IUniversity of Erlangen-NurembergErlangenGermany
  4. 4.Department of Pharmacology and Toxicology, Institute of PharmacyUniversity of BonnBonnGermany
  5. 5.Department of DermatologyUniversity of Erlangen-NurembergErlangenGermany
  6. 6.Institute of Human Genetics, Institute of Genetics and Center for Molecular Medicine Cologne (CMMC)University of CologneCologneGermany

Personalised recommendations